Child‑resistant packaging is defined by its intended functional quality, not by an absolute performance guarantee. The Order defines child‑resistant packaging as packaging designed or constructed to be difficult for young children to open within a reasonable time but not unduly difficult for adults to use properly (s 5, definition of child‑resistant packaging). The Order emphasises that child‑resistant is not synonymous with child‑proof (s 4(2), s 5 note).

Scope is determined by the substance contained in the medicine or by its labelling or presentation. Section 6 sets a twofold scope test. One limb captures registered medicines containing substances that fall within the classes in Part 1 of Schedule 1 (s 6(1)(a)). The second limb captures listed or registered medicines that contain individual substances set out in Part 2 of Schedule 1 when in the specified strength or pack size (s 6(1)(b)). A third limb brings in any medicine that is labelled or packaged in a way that states or implies to a consumer that the product, as presented, is child‑resistant (s 6(1)(c)).

Standards and testing regimes differ by package type. Reclosable packages are subject to a performance‑based regime: they must comply with at least one of the enumerated Standards, which include ISO 8317:2015, BS EN ISO 8317:2015, CSA Z76.1‑16, specified provisions of the US Code of Federal Regulations Title 16 Part 1700 (Sections 1700.15 and 1700.20), and AS 1928‑2007 (s 9(1)). Reclosable packages also trigger an evidentiary and documentation regime for sponsors, including maintaining certificates or information proving compliance and demonstrating that general requirements in s 8(2)-(3) are met (s 9(2)-(3)). Non‑reclosable packages are dealt with by design and materials criteria and do not require performance testing under this Order, though the Order contemplates developing best practice guidelines for such packaging (s 4(10)-(11), s 10).

Schedule 1 is rule‑based rather than exclusively risk scoring. The Order sets out criteria used to decide which substances are included in Schedule 1: toxicity and risk of harm on ingestion (with a working threshold of significant harm in a child of 11 kg), extent of availability, incident reports, consequences of incidents, the needs of patient groups who require ready access, and technical feasibility of child‑resistant packaging (s 4(4)-(6)). The Order makes clear that these criteria are balanced collectively and that public health and safety are given emphasis (s 4(7)).

Definitions are operationally important. For example, a restricted flow insert is specifically defined as an insert that is fitted or moulded into the neck of a container, cannot readily be removed by manual force, and limits delivery to drops not exceeding 200 microlitres (s 5). That definition is used in several Schedule 1 exemptions where small nominal container capacities fitted with such inserts are exempted from child‑resistant packaging requirements.

The Order separates policy recognition of human factors from the standards themselves. It recognises the difficulty child‑resistant packaging can pose for older persons and people with disability and references adult testing protocols in the enumerated Standards (s 4(8)). At the same time, s 8(4) prohibits packaging designs that require sight, unusual strength or unusual dexterity to access contents, which places a constraint on permissible child‑resistant mechanisms.

Record and evidence requirements create a documentary trail for compliance. For reclosable packages sponsors must hold certificates or equivalent information that unambiguously relates to the specific packaging used, and must maintain documentation on container types, suitability for medicine types, correct application of closures, and quality control testing for package components (s 9(2), (3), (5)). Sponsors must also obtain additional evidence if packaging specifications change (s 9(4)).

Exclusions are explicit and numerous. Section 7 lists categories of medicines to which the Order does not apply, including bulk medicine packs for repackaging by pharmacists that are labelled “For dispensing only”, injectable medicines, many topical preparations, small capacity ocular/aural containers under 20 mL or fitted with restricted flow inserts, export‑only medicines, and preparations not at their final stage of manufacture, among others (s 7(a)-(l)). These carve outs are material to commercial practice and distribution channels.

Finally, the Order deliberately delegates enforcement and penalties to the broader framework under the Therapeutic Goods Act and Regulations by stating that the Order’s requirements apply in addition to any other packaging requirements under the Act or Regulations (s 8(1)). The Order itself does not set out sanctioning provisions.

Primary regulatory duty is placed on sponsors. A sponsor is defined in s 5 as the person in relation to whom the medicine is registered or listed in the Register, or in relation to whom a medicine is exempt or the subject of an approval or authority. Sponsors of medicines that fall within the Schedule 1 scope, and of products labelled as child‑resistant, must ensure packaging complies with the Order and must hold the evidentiary and informational material required by s 9. They bear the compliance cost of testing, certification, record maintenance and, where necessary, revising packaging designs.

Manufacturers and packagers of medicines are operationally affected. The Order requires packaging to retain child‑resistant properties for the expected number of openings and to remain fit for purpose until the medicine expiry date (s 8(2)(a)-(b)). Manufacturers must therefore select materials and closures that meet those performance expectations and may need to supply sponsors with certificates, test data and quality control information as required by s 9(2)-(5).

Test agencies and certifiers are implicated in the reclosable package pathway. Sponsors are permitted to rely on certificates from test agencies attesting compliance with a Standard where the certificate clearly refers to the package specified by the sponsor (s 9(2)(a)). That creates demand for test agencies able to certify to the listed Standards.

Distributors, wholesalers and pharmacies are affected indirectly. The Order excludes bulk packs that are clearly labelled “For dispensing only” from its scope (s 7(a)), which recognises the commercial practice of dispensing pharmacists who repackage. Pharmacists who accept and repack must remain mindful that the bulk pack exemption is conditional on labelling and intended use. Retailers are exposed to the commercial impact of supplier compliance costs and any changes to pack formats that may alter shelf presentation or consumer usability.

Patients and consumers are impacted through product availability, package usability and safety. The Order recognises particular patient groups with special needs, such as older persons and people with disability, and requires that packaging must not be unduly difficult for adults to use (s 4(8), s 8(4)). Where sponsors select child‑resistant options that are compliant with Standards, adult usability remains a live concern. The Order’s exclusions also preserve access routes for medicines administered in hospitals or used by healthcare professionals (s 7(k)).

Hospitals, nursing homes, dental surgeries and institutional users are explicitly excluded where the medicine is to be used or administered for treatment in such facilities (s 7(k)). This shifts operational responsibility for securing safe storage and administration within those institutions away from the Order’s packaging prescription.

Exporters and importers are affected by the export‑only exclusion, which removes from scope medicines designated as export‑only under the Act (s 7(l)). However, where a product is supplied domestically or labelled as child‑resistant domestically, the Order applies.

Regulators are affected through oversight responsibilities embedded in the Act and Regulations. The Order does not itself create enforcement mechanisms, but it expands the substantive packaging obligations that regulators will consider when assessing compliance with the broader therapeutic goods framework (s 8(1)).

Finally, producers of small volume liquid products and essential oils have specific conditional exemptions dependent on nominal container capacity and the use of restricted flow inserts, as defined in s 5. Sponsors and manufacturers of those products must be aware that nominal container size and the presence of a restricted flow insert can change a product’s regulatory status under this Order.

Duties

• Scope determination. Sponsors must first determine whether a medicine is captured by the Order. The Order applies to registered medicines containing substances in the classes listed in Part 1 of Schedule 1 and to listed or registered medicines containing substances specified in Part 2 in the strengths or pack sizes specified (s 6(1)(a)-(b)). It also captures any other medicine labelled or packaged in a way that states or implies to a consumer that the product is child‑resistant (s 6(1)(c)). Determination is a factual and legal exercise that lies with the sponsor.

• Packaging performance and design. For any medicine to which the Order applies, packaging must remain fit for purpose until expiry and must retain child‑resistant properties for the expected number of openings and closings needed to use the contents (s 8(2)(a)-(b)). Packaging performance must not be adversely affected by the contents (s 8(3)). Packaging must not require sight, unusual strength or unusual dexterity to access contents or to re‑engage the child‑resistant feature (s 8(4)).

• Reclosable package obligations. If a medicine is in a reclosable package, the package must comply with at least one of the enumerated Standards (s 9(1)). The sponsor must hold evidence of compliance, which may be a certificate from a test agency or other information proving compliance (s 9(2)). Sponsors must also hold evidence demonstrating that s 8(2) and s 8(3) are met, and where specifications change, must obtain additional evidence that child‑resistant properties have not been adversely affected (s 9(3)-(4)). Sponsors must hold information on container types, suitability, correct application of closures, and quality control tests for component lots (s 9(5)). Reclosable packages must include conspicuous opening and reclosing directions in English or clear graphics (s 9(6)). If a separate applicator or dropper is packaged and is reasonably expected to replace the original closure, that configuration must also comply with the Order (s 9(7)).

• Non‑reclosable package requirements. Non‑reclosable packages must be blister or sealed strip formats made from specified materials and not formed from cellulose film or unlaminated paper (s 10(1)-(2)).

• Recordkeeping and evidence. The Order obliges sponsors to maintain and retain evidence and information supporting compliance. The forms of acceptable evidence are described, and there is an affirmative duty to obtain additional evidence following changes to package specifications (s 9(2), (3), (4), (5)).

Rights and administrative positions

• Right to rely on certified evidence. Sponsors are permitted to rely on certificates from test agencies attesting compliance with a Standard, provided the certificate unambiguously refers to the package used by the sponsor (s 9(2)(a)).

• Flexibility in evidence types. Where a package is not certified, the sponsor may hold other information that proves compliance with a relevant Standard, again provided the information clearly refers to the package specified by the sponsor (s 9(2)(b)). The Order also allows sponsors to rely on information demonstrating that a particular package has been previously established as complying with a relevant Standard (s 9(2)(c)).

• Exemptions and carve outs. Sponsors have the right to rely on express exclusions in s 7 where applicable. These include bulk medicine packs labelled “For dispensing only” (s 7(a)), injections (s 7(b)), certain topical products and small volume ocular/aural containers under 20 mL or fitted with restricted flow inserts (s 7(c)-(d)), export‑only medicines (s 7(l)) and institutional use products (s 7(k)). Sponsors must however ensure that the conditions of these exemptions are met.

• Label-based capture. A product that is marketed or labelled by a sponsor in a way that states or implies to a consumer that it is child‑resistant is brought within the Order’s scope even if its contents would not otherwise trigger Schedule 1 (s 6(1)(c)). This creates a practical right/responsibility: sponsors can exclude their products from the Order by avoiding such labelling, but if they use such labelling they accept the compliance obligations.

• Use of restricted flow inserts. The Order provides specific exemptions for certain essential oils and other listed substances where they are packaged in small nominal capacities with restricted flow inserts, as defined (s 5 and Part 2 entries). Sponsors can therefore use design features such as restricted flow inserts to meet the conditions for exemption.

Procedural implications

• Evidence must be "expressed in a way that makes it beyond doubt that the certification in fact refers to the package specified by the sponsor" (s 9(2)(a)-(b)). Sponsors therefore face a duty to ensure their certificates and testing information are specific to their packaging configuration.

• Changes to packaging specifications trigger a duty to obtain additional evidence (s 9(4)). Sponsors cannot assume prior certificates cover new container materials or closures without reassessment.

Overall, the Order places initial decision and ongoing compliance duties on sponsors, requires manufacturers and test agencies to support those duties, and reserves administrative enforcement to the broader regime under the Act and Regulations.

The Order itself does not specify penalty amounts, administrative fines, or enforcement procedures. It states that its requirements apply in addition to any other packaging requirements that may be applied to medicines under the Therapeutic Goods Act 1989 or the Therapeutic Goods Regulations 1990 (s 8(1)). Practically this means that enforcement, sanctioning and any civil or criminal penalties for non‑compliance will be derived from those parent statutes and subordinate instruments rather than from the Order.

Consequences of non‑compliance therefore fall within the enforcement architecture of the Act and Regulations, and may include actions that the regulator is empowered to take under those instruments. The Order creates substantive obligations that regulators can assess when exercising their statutory powers under the Act. Sponsors should therefore treat non‑compliance with the Order as non‑compliance with regulatory packaging requirements enforceable under the broader legislative framework.

Operational enforcement levers likely to be relevant include inspection, requests for information, directions to remedy packaging deficiencies, suspension or cancellation of registration or listing, recalls, or other regulatory actions that the Act and Regulations empower the regulator to take. The Order does not itself describe which of those levers will be used, nor the procedures for notices, review, or appeals.

Because the Order places evidentiary and documentation obligations on sponsors, enforcement is likely to focus on documentary proof and test results. Section 9 requires sponsors to hold specified forms of evidence showing compliance with a relevant Standard and to hold information relevant to the packaging configuration and quality control (s 9(2)-(5)). Regulators enforcing the Order will therefore have a clear evidentiary focus. Failure to maintain or produce the required documentation may itself be treated as non‑compliance.

The Order also contemplates that the Standards will include test protocols, including protocols that test performance against adult usability and child resistance (s 4(8), s 9(1)). Where sponsors rely on test agency certificates, the content and specificity of those certificates are material; s 9(2)(a) requires a certificate to be expressed in a way that makes it beyond doubt that the certificate refers to the package specified by the sponsor. A regulator assessing compliance will therefore scrutinise certificates for specificity.

Finally, the Order creates some compliance risk where exemptions are conditional. For example, exemptions that depend on nominal container capacity and the presence of a restricted flow insert mean that a sponsor who mismeasures nominal capacity or uses a removable insert could lose the exemption and be non‑compliant (see s 5 definition of restricted flow insert and the Part 2 Schedule 1 exemptions). Enforcement action may therefore arise from factual disputes over whether the conditions for an exemption are met.

In short, while the Order does not itself set out penalties, it expands the substantive packaging obligations that regulators will use the Act and Regulations to enforce, and it places documentary and technical evidentiary burdens on sponsors that will be central to regulatory compliance assessments.

The Order is a subordinate instrument made under section 10 of the Therapeutic Goods Act 1989, and it explicitly situates itself as supplementary to other packaging requirements under the Act and Regulations (s 8(1)). This means that compliance with the Order is necessary but not sufficient where other statutory or regulatory packaging obligations apply.

Definitions in the Order reference terms and regimes established in the Act and Regulations. For instance, the Order uses the Act’s meanings for "container", "primary pack", "Register", "listed medicine", "registered medicine", "export only medicine" and "indications" (s 5). These cross‑references mean that a full legal assessment of obligations will require consulting the Act and Regulations to understand registration/listing status, export only designations, and other regimen that affect whether a product falls within the Order.

The Order sits alongside the previously issued Therapeutic Goods Order No. 80. The transition regime allowed sponsors to comply with either TGO 80 or this Order until 30 September 2018, and provided that TGO 80 would sunset on 1 October 2018 under the Legislation Act 2003 (s 3 and the accompanying note). This shows an interaction between statutory instruments and the Legislation Act in managing sunset and repeal timings.

Because the Order binds sponsors through obligations tied to registration or listing status, other duties under the Act such as recordkeeping, notification obligations, recall procedures, and advertising restrictions continue to apply. The Order does not displace those duties; rather, it expands packaging obligations that must be met in addition to them (s 8(1)).

The Order also intersects with consumer protection and labelling regimes indirectly. Section 6(1)(c) brings into scope any product that is labelled or packaged in a way that states or implies to a consumer that the product is child‑resistant. This means that promotional or packaging representations governed by other laws, such as general consumer law requirements on representations to consumers, or labelling obligations under the Act and Regulations, will interact with this Order. A sponsor that markets a product as “child‑resistant” must ensure the packaging actually complies with the Order.

International standards referenced in s 9(1) create technical interoperation with foreign regulatory regimes. By permitting compliance with ISO 8317:2015, BS EN ISO 8317:2015, CSA Z76.1‑16, the US CFR provisions in Title 16 Part 1700, and Australian AS 1928‑2007, the Order allows sponsors to rely on testing and certification from diverse jurisdictions. However, the Order requires that the certificate or information unambiguously refer to the sponsor’s specific packaging (s 9(2)), which moderates simple portability of foreign certificates.

Where products are exported only, the Order excludes them from its scope (s 7(l)). That interacts with the Act’s definition and administrative treatment of export‑only medicines. Importers and exporters must therefore understand the Act’s export classification regime to determine whether the Order applies.

The Order’s materials and design prescriptions for non‑reclosable packages (s 10) may interact with other Australian standards and state or territory environmental or waste laws where material selection is subject to separate regulation. The Order forbids cellulose film and unlaminated paper for non‑reclosable packages (s 10(2)), which will influence material sourcing and supply chain decisions.

Finally, the Order’s safety rationale and the requirement that packaging not be adversely affected by the contents (s 8(3)) interacts with manufacturing and product safety obligations under the Act. Sponsors must therefore ensure that pharmaceutical formulation, stability and packaging compatibility are considered holistically, and that any regulatory submissions or notifications under the Act reflect those considerations.

The Order as presented is dated 29 November 2017 and was determined by the Delegate of the Minister for Health under section 10 of the Therapeutic Goods Act 1989. It states that it commences on the day after it is registered (s 2). The instrument contains a targeted transition provision which allowed sponsors to comply with either this Order or Therapeutic Goods Order No. 80 until 30 September 2018, and provided that on and after 1 October 2018, each medicine to which the Order applies must comply with this Order (s 3). The accompanying note records that under the Legislation Act 2003, TGO 80 would sunset on 1 October 2018.

No other amendments, revocations, saving or expiry clauses are included in the text provided. The Order sets out its operative provisions, definitions, scope and Schedule 1 substance lists without indicating later amendments or schedules beyond those contained herein.

The Order contemplates future guidance or further work for non‑reclosable packaging. Section 4(11) states that it is intended that a best practice guideline on non‑reclosable packaging will be developed to help sponsors improve robustness and effectiveness of blister or foil strip packaging. This indicates an administrative intention to supplement the Order with non‑statutory guidance, but it does not itself amend the Order or create legislative change.

Where packaging specifications change for a sponsor’s product, the Order requires the sponsor to obtain additional evidence demonstrating that the child‑resistant properties have not been adversely affected (s 9(4)). This is an operational requirement rather than a legislative amendment mechanism.

Because the Order references external Standards by date and edition, future updates to those Standards could have practical impact. However, the Order expressly ties compliance to the versions named at the time of the Order, for example ISO 8317:2015 and AS 1928‑2007 (s 9(1)). Any change in legislative effect arising from updates to those Standards would require amendment of the Order or administrative interpretation.

If a party is relying on an older instrument such as TGO 80, the transition provision and the note on TGO 80 sunset clarify the legal timeline for the legislative changeover: dual compliance options existed only until 30 September 2018 (s 3). After that date, the requirement is to comply with this Order.

The Order’s Schedule 1 contains a comprehensive list of classes and substances. The Order provides that class names reflect the ATC system and that classes shown include any substance under the given ATC classification unless specifically exempted (Schedule 1, Part 1 note). Any subsequent amendment to Schedule 1 by the competent delegate would change the scope; the Act’s powers to vary Orders permit such updates, but no such variations are contained in this document.

In sum, the text indicates a discrete instrument established in late 2017, replacing earlier TGO 80 from 1 October 2018. It anticipates non‑statutory guidance on non‑reclosable packages but contains no recorded subsequent legislative amendments in the text provided.

The Order as provided contains no references to judicial decisions, appeals, administrative tribunal determinations, or enforcement adjudications. There are no cases named in the instrument, nor are there references to past litigation or precedent. The Order is a legislative instrument setting standards and administrative duties; it does not itself record litigation history.

Practitioners should therefore note two practical implications. First, because the Order is silent on litigation and enforcement processes, disputes about its application, interpretation, or compliance will be resolved under the dispute resolution and enforcement mechanisms provided by the Therapeutic Goods Act 1989 and general administrative law principles. Any contested enforcement action or regulatory decision relating to compliance with this Order will therefore proceed through the procedural and review pathways established by the Act and applicable administrative law. The Order’s silence on enforcement specifics means that enforcement outcomes, sanctions, and appeal rights are to be found in the parent statute and associated regulations and practice notes.

Second, absence of litigation history in the instrument increases the evidentiary importance of compliance documentation in enforcement contexts. Section 9 places specific obligations on sponsors to hold certificates or information proving compliance with relevant Standards, to retain evidence that general packaging performance requirements are met, and to obtain additional evidence when specifications change (s 9(2)-(4)). In an enforcement or dispute scenario, regulatory bodies will likely focus on whether the sponsor maintained the specific documentary and test evidence the Order requires. Litigation about alleged non‑compliance will therefore be documentary and technical in nature, turning on test reports, certificates, package specifications, and the factual circumstances of the product’s presentation and labelling.

Because the Order references Standards and testing protocols that include child and adult test panels (s 4(8), s 9(1)), future litigation could engage expert evidence on testing methodology and on whether a given package as used in practice meets the technical performance thresholds. Practitioners should therefore anticipate that contested matters will require technical expert reports on packaging performance and may involve dispute over whether certificates or test evidence specifically apply to the packaging configuration used by the sponsor, given the Order’s insistence that certificates must make it "beyond doubt" that they refer to the sponsor’s package (s 9(2)(a)).

Finally, the Order’s coverage that a product labelled or packaged as child‑resistant falls within scope (s 6(1)(c)) creates a litigation risk where a sponsor’s marketing or labelling statements are ambiguous. Any dispute over whether labelling "states or implies" child‑resistance may be a question of fact and interpretation, potentially giving rise to reviewable regulatory decisions or tribunal proceedings. In the absence of precedent recorded in the instrument, parties should expect that litigation may develop factual lines on these interpretive questions.

In short, the Order itself records no litigation history. Legal disputes about its application will invoke the Act, administrative law, and technical evidence on packaging performance and documentary compliance.

Several practical traps and non‑obvious rules in the Order can catch sponsors, manufacturers and compliance teams.

1. Label or presentation capture. Section 6(1)(c) brings within the Order any medicine labelled or packaged in a way that states or implies to a consumer that the product is child‑resistant. A sponsor that uses marketing text, logos, icons or packaging that implies child‑resistance will trigger the Order even if the product’s contents would not otherwise be listed in Schedule 1. Avoiding inadvertent capture therefore requires careful control of packaging claims.

2. Class coverage and ATC inclusions. Part 1 of Schedule 1 lists substance classes by common names and notes that class names reflect the ATC classification system and include any substance under a given ATC classification unless specifically exempted (Schedule 1, Part 1 note). Sponsors must map their active substances to ATC classes to determine capture, and watch for specific exclusions in Part 2.

3. Conditional exemptions tied to nominal container capacity and restricted flow inserts. Multiple entries in Part 2 exempt certain essential oils and other substances when packed in containers below a specified nominal capacity and fitted with a restricted flow insert (see numerous entries in Part 2 and definition of restricted flow insert in s 5). The restricted flow insert is defined narrowly: it must be fitted or moulded into the neck, not readily removable by manual force, and must limit delivery to drops not exceeding 200 microlitres (s 5). If a sponsor uses removable inserts, or if actual filled volume exceeds the nominal capacity threshold, the exemption may not apply.

4. Non‑reclosable packages are not performance tested under this Order. Section 4(10) confirms that requirements for non‑reclosable packages do not involve performance testing at this time, but are based on design and materials. Sponsors relying on blister/strip formats should be aware that the Order contemplates a later best practice guideline (s 4(11)). The absence of a performance testing requirement does not remove the general obligations in s 8 that packaging remain fit for purpose and not be adversely affected by contents.

5. Reclosable package compliance requires evidence specific to the package. Section 9(2)(a) requires certificates to be expressed in a way that makes it beyond doubt that the certification refers to the package specified by the sponsor. Generic certificates, or certificates referring to a different closure or container size, risk being insufficient.

6. Changes to specifications trigger re‑testing or additional evidence. If a sponsor changes closure material, container size, or other packaging specifications, s 9(4) requires additional evidence demonstrating that child‑resistant properties are unchanged. Sponsors should not assume prior testing covers altered configurations.

7. Adult usability constraint. Section 8(4) prohibits packaging designs that require sight, unusual strength or unusual dexterity to access contents or re‑engage the child‑resistant feature. While the Standards include adult testing protocols for ages 50 to 70 (s 4(8)), sponsors must balance child resistance with adult accessibility. Overly aggressive child‑resistant mechanisms risk falling foul of s 8(4).

8. Packaging must withstand contents until expiry. Section 8(2)(a) requires the packaging to remain fit for purpose until the expiry date. Where contents are chemically aggressive or volatile, sponsors must ensure compatibility and stability testing to show packaging performance over shelf life.

9. Packaging together with applicators. If a product is packaged with a separate dropper or applicator reasonably expected to replace the original closure in use, that configuration must comply with the Order (s 9(7)). Sponsors who supply secondary applicators must evaluate the combined system.

10. Bulk pack exemption is conditional on labelling. The bulk medicine pack exemption applies only where the container is intended only as a bulk medicine pack and is clearly labelled "For dispensing only" and "This pack not to be supplied to a patient" or words to that effect (s 7(a)). Labelling errors, or distribution of a bulk pack to patients, could remove the exemption.

11. Certain topical and institutional products excluded. The Order excludes many topical skin or mucous membrane products and medicines intended for institutional administration (s 7(c), (k)). Sponsors that market products both to institutions and to retail consumers should carefully segregate supply chains and labelling to maintain the exclusion.

12. Definition of young children. The Order adopts the age range specified in the protocols given in the referenced Standards for testing child resistance, namely 42 to 51 months inclusive (s 5 note). Where testing is used, sponsors must ensure that the tests match the referenced protocols.

13. No explicit penalties in the Order. The Order relies on the Act and Regulations for enforcement (s 8(1)). Sponsors must therefore map packaging compliance into the broader regulatory obligations under the Act to understand sanctions that may follow.

14. Documentation specificity. The requirement that evidence be unambiguously tied to a sponsor’s package raises an administrative challenge for global supply chains that use common closures across multiple products. Sponsors must ensure that certificates and test reports explicitly name the container and closure combination used in their particular product.

15. International standards and editions. The Order names specific Standards by edition and year (for example ISO 8317:2015 and AS 1928‑2007) (s 9(1)). Sponsors relying on certifications to earlier or later editions should verify that the certification references the edition named or obtain evidence under the stated edition.

These practical risks mean that compliance requires active record management, conservative labelling practices, careful selection of material and closure suppliers, and control over specification changes.

Stepwise compliance checklist grounded in the Order provisions.

1. Scope assessment. Start by determining whether the medicine is within scope under s 6. Check whether the active substance falls within a class listed in Schedule 1 Part 1, or is an individual substance in Part 2 where the strength or pack size matches the Schedule entry (s 6(1)(a)-(b)). Also check packaging and labelling claims that might trigger s 6(1)(c).

2. Confirm exclusions. If captured, determine whether any explicit exclusion in s 7 applies, for example bulk packs labelled “For dispensing only” (s 7(a)), injectables (s 7(b)), topical products (s 7(c)), small ocular/aural containers under 20 mL (s 7(d)(i)) or those fitted with a restricted flow insert (s 7(d)(ii)), export‑only medicines (s 7(l)), or institutional use products (s 7(k)). If an exemption is relied upon, document the factual basis and retain evidence such as labelling and packaging specifications.

3. Decide package type. Determine whether the product will be supplied in a reclosable package or a non‑reclosable package (s 5 definitions and s 9-10). If non‑reclosable, ensure the package conforms to s 10: blister or sealed strip formed from paper, film, plastic, metal foil or other sheet material, enclosing single dosage units, and not formed from cellulose film or unlaminated paper (s 10(1)-(2)). For reclosable packages, move to the Standards pathway.

4. Reclosable Standards compliance. For reclosable packaging, achieve compliance with at least one of the listed Standards in s 9(1). Choose a Standard and commission testing to the protocol for that Standard, or obtain certification from an accredited test agency. Ensure the testing uses the child and adult protocols referenced by the Standard so that the sponsor can demonstrate performance consistent with s 4(8) and s 9(1).

5. Evidence documentation. Collect and retain evidence in the acceptable forms set out in s 9(2). That may be a test agency certificate that expressly identifies the sponsor’s package and the protocol used, or alternative documentation that proves compliance and unambiguously refers to the sponsor’s package, or evidence that the package has been previously established compliant (s 9(2)(a)-(c)). Ensure certificates or reports name specific container and closure combinations and the relevant Standard edition.

6. General performance validation. Collect evidence demonstrating compliance with s 8(2) and s 8(3), namely that the packaging remains fit for purpose until expiry and that contents do not adversely affect child‑resistant performance. This may require stability testing or materials compatibility testing over shelf life.

7. Maintain package specification records. Keep detailed information on the types and sizes of containers relevant to the closure, the suitability of the package for the type of medicine, production line application processes, and the quality control tests applied to components (s 9(5)(a)-(d)). Record manufacturing tolerances, torque specifications, and closure engagement criteria.

8. Change control. Implement a formal change control process so that any alteration to packaging specifications triggers an assessment and, if required, additional testing or evidence collection per s 9(4). Do not rely on historical certificates without confirming applicability to the changed configuration.

9. Labelling and directions. Ensure that reclosable packages carry conspicuous directions for opening and effectively reclosing in English or clear graphics (s 9(6)). Where a product includes a separate applicator or dropper reasonably expected to replace the original closure, validate the combined system as required by s 9(7).

10. Restricted flow insert use. If seeking an exemption conditioned on restricted flow inserts or small nominal capacities, verify the insert meets the s 5 definition: fitted or moulded into the neck, not readily removable by manual force, and limits delivery to drops not exceeding 200 microlitres. Document insert design, method of attachment and testing to show non‑removability and drop volume.

11. Special patient groups. Where medicines are likely to be used by older persons or people with disability, ensure design choices comply both with child‑resistant testing protocols and s 8(4) constraint on requiring sight, unusual strength or unusual dexterity. Retain adult usability test evidence where relevant.

12. Record retention and availability. Keep all certificates, test reports, change records, and quality control data in an accessible format so they can be produced to regulators on request. Ensure certificates explicitly identify the packaging configuration used by your product.

13. Supply chain coordination. Ensure that all suppliers of closures and containers understand the need to maintain lot‑specific quality control testing and to provide documentation that confirms that production lots of package components are of consistent and satisfactory quality and appropriate for use (s 9(5)(d)).

14. Internal audit. Conduct periodic internal audits to confirm continuing compliance with s 8 and s 9. Review packaging performance data, consumer complaints, and any stability or compatibility issues that may arise in market use.

15. Revisit labelling claims. If you wish to remove your product from the Order’s scope, remove labelling or packaging claims that state or imply child‑resistance. If you wish to market a product as child‑resistant, prepare to meet the full evidentiary requirements in s 9.

16. Keep abreast of guidance. The Order contemplates best practice guidance on non‑reclosable packaging (s 4(11)). Monitor regulator communications for any non‑statutory guidelines or updates to interpretive practice.

Implementation practicalities

• Where relying on third party certificates, ensure contractual arrangements require that certificates name your product’s container and closure and that test agencies comply with the requested protocol versions.

• For multi‑market products, obtain certificates that either refer to the specific edition of the Standard listed in s 9(1) or obtain new testing demonstrating compliance with the edition specified in the Order.

• For products using blister packs, ensure that pocket size and press force maintain single‑unit access and that materials conform to s 10, avoiding excluded materials such as cellulose film or unlaminated paper.

Following this checklist will address the main substantive and documentary obligations the Order imposes on sponsors and their supply chains.